Compared effect of a genetically engineered glucagon and hyoscine N-butylbromide on double-contrast barium meal study

Abstract

The aim of this study was to compare the effects of a genetically engineered glucagon (geG) and hyoscine N-butylbromide (HBB) on the quality of double-contrast barium meal (DCBM) study. Two hundred sixty-four patients scheduled for DCBM were randomized to receive intravenously geG 0.25 mg (geG-25), or geG 0.5 mg (geG-50), or HBB 20 mg as hypotonic agent. The evaluation concerned: duration of isolated visualization of the stomach (A); gastric mucosal coating (B); visualization of areae gastricae (C); quality of duodenal cap (D) and loop (E) study; delay, if any, of duodenal study (F). Global significant differences (P from 0.0183 to < 0.0001) were found for A, C, D, and F. GeG-50 allowed the longest isolated gastric visualization (P < 0.0001); geG-25 allowed more extensive visualization of areae gastricae than HBB (P = 0.0006); HBB allowed a better study of duodenal cap (P = 0.0052) and loop (P = 0.0190) than geG-25; geG-50 prolonged the examination time (P < 0.01). No adverse effect was observed with geG within 1 h after DCBM. In conclusion, geG can be safely used as a hypotonic agent in DCBM. When DCBM is focused on the stomach, 0.25 mg of geG is the optimal choice; if DCBM is focused on the duodenum, 0.5 mg of geG (with a prolonged examination time) or 20 mg of HBB (with a less effective study of the stomach) should be used.

Aperistaltic effect of hyoscine N-butylbromide versus glucagon on the small bowel assessed by magnetic resonance imaging

“…Various other authors [10][11][12] have already qualitatively compared the spasmolytic, duodenal distension and coating effects of glucagon and HBB in double-contrast barium meal examinations. Prolonged gastric visualization was reported with 0.5 mg i.v.…”

Administration ofhyoscine- n-butylbromideduring colonoscopy: a survey of current UK practice: Table 1

“…It competes with acetylcholine producing an antagonist effect on the muscarinic receptors of the parasympathetic system 9 10. It is non-selective and thus produces a number of autonomic responses depending on the dose administered.…”

Cardiovascular effects of N‐butylscopolammonium bromide and xylazine in horses

“…2008). NBB and NBB‐hyoscine are anticholinergic agents, similar to atropine and scopolamine, which compete with acetylcholine and produce an antagonistic effect on muscarinic receptors of the parasympathetic nervous system (Cittadini et al . 1998; Margues et al .…”

“…NBB-hyoscine is also available in Europe for human use and is commonly used to treat gastrointestinal pain and to facilitate diagnostic procedures such as angiography, colonoscopy and barium enema (Dyde et al 2008). NBB and NBB-hyoscine are anticholinergic agents, similar to atropine and scopolamine, which compete with acetylcholine and produce an antagonistic effect on muscarinic receptors of the parasympathetic nervous system (Cittadini et al 1998;Margues et al 1998;Roach et al 2001;Dyde et al 2008). As with the majority of muscarinic antagonists, they are nonselective and thus produce a number of autonomic responses (Dyde et al 2008).…”